Metformin for Longevity: The Complete Guide

Overview

Metformin (dimethylbiguanide) is one of the most widely prescribed medications in the world. Derived from the French lilac plant (Galega officinalis), it has been used as a first-line treatment for type 2 diabetes since the late 1950s in Europe and since 1995 in the United States. Over six decades of clinical use have established an extensive safety profile in diabetic populations.

Interest in metformin as a longevity intervention emerged from a convergence of observations: diabetic patients taking metformin appeared to live longer than expected — in some analyses, longer than matched non-diabetic controls (Bannister et al., 2014). Laboratory studies revealed that metformin activates cellular pathways strongly associated with lifespan extension across species, including AMPK activation and mTOR inhibition. Animal studies demonstrated lifespan extension in multiple organisms including C. elegans, mice, and rats.

These converging lines of evidence led Nir Barzilai and colleagues at the Albert Einstein College of Medicine to propose the TAME trial — Targeting Aging with Metformin. The TAME trial represents a landmark in aging research: the first clinical trial designed specifically to test whether a pharmaceutical intervention can delay the onset of age-related diseases as a composite endpoint, effectively treating "aging" rather than any single disease (Barzilai et al., 2016).

The longevity use of metformin remains a subject of active scientific debate. Proponents point to its broad effects on aging-associated pathways, favorable safety profile, low cost, and decades of clinical experience. Critics note that the observational human data is subject to confounding, the animal data is inconsistent across strains, and emerging evidence suggests metformin may blunt some of the benefits of exercise — itself one of the most robustly supported longevity interventions (Konopka et al., 2019).

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

AMPK Activation

AMP-activated protein kinase (AMPK) is a master regulator of cellular energy homeostasis. When cellular energy is low (high AMP:ATP ratio), AMPK activates catabolic pathways that generate ATP and suppresses anabolic pathways that consume it. Metformin activates AMPK indirectly, primarily through partial inhibition of mitochondrial Complex I, which reduces ATP production and raises the AMP:ATP ratio (Hardie, 2013).

AMPK activation is relevant to longevity because it:

• Stimulates autophagy — the cellular recycling process that clears damaged proteins and organelles
• Enhances mitochondrial biogenesis and function
• Reduces inflammatory signaling (NF-κB pathway)
• Improves insulin sensitivity
• Inhibits mTOR signaling (see below)

AMPK activity declines with age across tissues. Pharmacological restoration of AMPK signaling is hypothesized to recapitulate some benefits of caloric restriction (Hardie, 2013).

mTOR Inhibition

The mechanistic target of rapamycin (mTOR) is a nutrient-sensing kinase that promotes cell growth, protein synthesis, and proliferation when nutrients are abundant. Chronic mTOR activation is associated with accelerated aging, cancer, and metabolic dysfunction. Inhibition of mTOR — genetically or pharmacologically (e.g., rapamycin) — extends lifespan in yeast, worms, flies, and mice.

Metformin inhibits mTOR signaling through both AMPK-dependent and AMPK-independent mechanisms. AMPK directly phosphorylates TSC2, which inhibits mTORC1. Metformin also inhibits Rag GTPase-mediated mTORC1 activation independently of AMPK (Bannister et al., 2014). This dual mechanism of mTOR suppression is considered a key component of metformin's potential anti-aging effects.

Mitochondrial Complex I Inhibition

Metformin's primary molecular target is mitochondrial Complex I (NADH:ubiquinone oxidoreductase) in the electron transport chain. Partial inhibition of Complex I reduces the rate of oxidative phosphorylation, lowers ATP production, and increases the AMP:ATP ratio — triggering AMPK activation. This mild energetic stress is thought to activate protective stress-response pathways (hormesis) without causing overt cellular damage (Hardie, 2013).

Reduction of Hepatic Glucose Production

In its approved indication for diabetes, metformin's primary therapeutic mechanism is reducing hepatic glucose output. It suppresses gluconeogenesis in the liver through AMPK-dependent and AMPK-independent pathways. This reduces fasting blood glucose and insulin levels. Lower circulating insulin is relevant to longevity because chronic hyperinsulinemia is associated with accelerated aging, cancer risk, and cardiovascular disease.

Anti-Inflammatory Effects

Metformin reduces systemic inflammation through several mechanisms:

• Inhibition of NF-κB signaling via AMPK activation
• Reduced production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)
• Modulation of macrophage polarization toward anti-inflammatory phenotypes
• Reduction in advanced glycation end-products (AGEs), which drive inflammatory aging ("inflammaging")

Chronic low-grade inflammation ("inflammaging") is a hallmark of aging and a driver of age-related diseases. Metformin's anti-inflammatory properties are considered relevant to its potential longevity benefits (Campbell et al., 2017).

Effects on the Gut Microbiome

Metformin alters the composition of the gut microbiome, increasing the abundance of short-chain fatty acid (SCFA)-producing bacteria such as Akkermansia muciniphila. SCFAs have anti-inflammatory, metabolic, and gut barrier-protective effects. Some researchers have proposed that a portion of metformin's metabolic benefits — and its GI side effects — are mediated through microbiome modulation rather than direct cellular effects (Campbell et al., 2017).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Bannister et al. (2014) — The Landmark Observational Study

This retrospective cohort study using UK Clinical Practice Research Datalink compared survival in type 2 diabetic patients initiated on metformin monotherapy versus matched non-diabetic controls. The analysis included over 78,000 metformin-treated patients and 90,000 controls. The finding: metformin-treated diabetics had 15% lower all-cause mortality than non-diabetic controls, despite having the metabolic burden of diabetes (Bannister et al., 2014).

This study was pivotal in shifting metformin from a diabetes drug to a longevity candidate. However, important caveats apply:

• Observational design cannot establish causation
• Metformin users may differ systematically from controls (healthy user bias, more frequent medical monitoring)
• The non-diabetic control group was not receiving any specific intervention
• Confounding by indication is inherent in any observational comparison of treated patients versus untreated populations

Campbell et al. (2017) — Microbiome and Metabolic Effects

This study demonstrated that metformin produces significant changes in the gut microbiome composition of treatment-naive type 2 diabetic patients, with enrichment of Akkermansia muciniphila and SCFA-producing bacteria. The study used a randomized, double-blind, placebo-controlled design and included fecal microbiota transplant experiments showing that metformin-altered microbiota could independently improve glucose tolerance in germ-free mice (Campbell et al., 2017).

Relevance to longevity: gut microbiome composition changes with aging, and restoration of a "younger" microbiome profile is an active area of longevity research. Metformin's microbiome effects may contribute to its metabolic and anti-inflammatory benefits.

Konopka et al. (2019) — Metformin and Exercise Interactions

This randomized, double-blind, placebo-controlled trial examined whether metformin (2,000 mg/day) combined with aerobic exercise training affected cardiorespiratory fitness and insulin sensitivity in older adults (62–70 years). The key finding: metformin blunted the improvement in whole-body insulin sensitivity and cardiorespiratory fitness (VO₂max) that exercise alone produced. The exercise-only group showed a 25% improvement in insulin sensitivity; the metformin-plus-exercise group showed no significant improvement (Konopka et al., 2019).

This study raised important questions for the longevity community:

• Exercise is one of the most robustly supported longevity interventions
• If metformin attenuates exercise benefits, the net effect on healthspan could be negative for physically active individuals
• The interaction may be dose-dependent — the study used a relatively high dose (2,000 mg/day)
• The study population was older adults; effects in younger populations are unknown
• Mitochondrial adaptations to exercise require the same stress signals (ROS, energy depletion) that metformin modulates

The TAME Trial (Targeting Aging with Metformin)

The TAME trial, led by Nir Barzilai at the Albert Einstein College of Medicine, is a multicenter, randomized, double-blind, placebo-controlled trial designed to test whether metformin can delay the onset of age-related diseases as a composite endpoint. Key details:

The TAME trial is significant beyond its specific results because it established a regulatory framework for testing aging interventions. If metformin demonstrates benefit against the composite endpoint, it could open the pathway for FDA recognition of aging as a targetable condition (Barzilai et al., 2016).

Animal Lifespan Studies

• C. elegans: Metformin extended lifespan by approximately 18–36% depending on the study and dose, with effects dependent on AMPK signaling (Onken & Driscoll, 2010).
• Mice (C57BL/6): Low-dose metformin (0.1% in diet) extended mean lifespan by approximately 5.83% in male C57BL/6 mice. Higher doses (1% in diet) were toxic and shortened lifespan (Martin-Montalvo et al., 2013).
• Mice (strain variation): Lifespan effects are inconsistent across mouse strains. Some strains show no benefit or harm. This strain-dependence raises questions about genetic modifiers of metformin response in humans.
• Rats: Mixed results. Some studies show modest lifespan extension; others show no effect or reduced lifespan at higher doses.

Cancer Risk Reduction

Multiple observational studies and meta-analyses have reported reduced cancer incidence and cancer mortality among metformin users compared to other diabetes treatments. A meta-analysis of 47 studies reported a 31% reduction in overall cancer incidence among metformin users (Gandini et al., 2014). mTOR inhibition, AMPK activation, and reduced insulin/IGF-1 signaling are proposed mechanisms. However, prospective randomized trials specifically testing metformin for cancer prevention have yielded mixed results, and the observational data is subject to substantial confounding.

Limitations of the Evidence

• No completed prospective longevity trial in humans: The TAME trial is ongoing; results are not yet available.
• Observational data limitations: The Bannister 2014 finding, while striking, cannot establish causation and is subject to multiple biases.
• Exercise interaction: The Konopka 2019 findings remain unresolved — whether the net effect of metformin plus exercise is positive or negative for healthspan is unknown.
• Animal model inconsistency: Lifespan extension is dose- and strain-dependent, with some models showing harm at higher doses.
• Population specificity: Most human data comes from diabetic populations. Extrapolation to metabolically healthy non-diabetic individuals is uncertain.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

• Type 2 diabetes mellitus: First-line pharmacotherapy, typically in combination with lifestyle modifications (diet and exercise). Approved as monotherapy and in combination with other antidiabetic agents.

Off-Label Uses Relevant to Longevity

Who Is Using Metformin for Longevity

Metformin for longevity is prescribed by physicians in integrative medicine, preventive medicine, and longevity-focused practices. It is typically prescribed to non-diabetic individuals who:

• Have metabolic risk factors (elevated fasting glucose, insulin resistance, metabolic syndrome) that do not yet meet diagnostic criteria for diabetes
• Seek pharmacological support for healthy aging alongside lifestyle interventions
• Have a family history of age-related diseases (cardiovascular disease, cancer, dementia)
• Are awaiting TAME trial results but wish to begin treatment based on existing evidence

Metformin is not typically recommended as a standalone longevity intervention. Most longevity-focused clinicians prescribe it as one component of a broader program that includes exercise, nutrition, sleep optimization, and other evidence-based interventions.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Longevity Protocols

Dosing protocols above are derived from clinical practice in longevity medicine, the TAME trial design (Barzilai et al., 2016), and standard diabetes prescribing guidelines. No FDA-approved longevity dosing exists.

Titration Schedule

Most clinicians titrate metformin gradually to minimize GI side effects:

• Week 1–2: 500 mg ER once daily with dinner
• Week 3–4: 500 mg ER twice daily (if targeting higher dose) or maintain at 500 mg
• Week 5–6: Increase to target dose (1,000–1,500 mg/day) if tolerated
• Reassess: Monitor fasting glucose, HbA1c, B12 levels, and kidney function (eGFR/creatinine)

Extended-Release vs. Immediate-Release

Extended-release (ER) metformin is used in most longevity protocols because:

• Significantly fewer GI side effects (nausea, diarrhea) compared to immediate-release (IR)
• Once-daily dosing improves adherence
• Comparable metabolic effects to IR at equivalent total daily doses
• Available as inexpensive generic

Timing Considerations

• With meals: Metformin should be taken with food to reduce GI side effects
• Evening dosing: Some longevity practitioners prefer evening dosing to target overnight hepatic glucose production
• Exercise timing: Given the Konopka 2019 data on exercise blunting, some practitioners advise skipping metformin on high-intensity training days — though this practice is not supported by controlled trial data

Monitoring

• Baseline labs: Fasting glucose, HbA1c, comprehensive metabolic panel (including creatinine/eGFR), vitamin B12, CBC
• Ongoing: B12 levels every 6–12 months (long-term depletion is documented); kidney function annually; metabolic markers as clinically indicated
• Contraindication screening: eGFR <30 mL/min/1.73m² is a contraindication; eGFR 30–45 requires dose reduction and close monitoring

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Is Known

Observational Mortality Data

Biomarker Effects

In studies of diabetic and pre-diabetic populations, metformin has demonstrated measurable effects on aging-associated biomarkers:

• Reduced fasting insulin and HOMA-IR (insulin resistance index)
• Lower C-reactive protein (CRP) and other inflammatory markers
• Improved lipid profiles (modest reductions in LDL and triglycerides)
• Reduced HbA1c and fasting glucose (primary diabetes effects)
• Lower IGF-1 levels in some studies (relevant to mTOR/growth signaling)

What Users in Longevity Communities Report

Anecdotal reports from longevity-focused users (non-diabetic individuals taking metformin off-label) commonly include:

• Modest reduction in fasting glucose (typically 5–15 mg/dL)
• Reduced appetite and minor weight loss (2–5 lbs)
• GI side effects as the primary negative experience, particularly in the first 2–4 weeks
• No subjectively noticeable "anti-aging" effect — users emphasize that benefits, if real, are expected to manifest over decades
• Some physically active users report perceived reduction in exercise performance, consistent with the Konopka 2019 findings

What Results Will the TAME Trial Provide

The TAME trial is designed to answer whether metformin delays the composite onset of cardiovascular disease, cancer, dementia, and mortality in non-diabetic older adults. If positive, it would provide the first prospective evidence that a pharmacological intervention can slow the aging process in humans. Results are expected after the trial's 6-year follow-up period is complete.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects

Serious Side Effects

Vitamin B12 Depletion — A Key Long-Term Concern

Metformin-induced B12 depletion is well-documented and clinically significant for long-term longevity use:

• Mechanism: metformin interferes with calcium-dependent B12–intrinsic factor complex absorption in the terminal ileum
• Onset: typically develops gradually over 1–3 years of continuous use
• Consequences if unmonitored: peripheral neuropathy (which can be misattributed to diabetic neuropathy in diabetic patients), megaloblastic anemia, cognitive impairment, elevated homocysteine
• Management: regular B12 level monitoring (every 6–12 months); supplementation with oral B12 (1,000 mcg/day) or periodic intramuscular B12 injections as needed

Exercise-Blunting Effect

The Konopka 2019 findings suggest metformin may attenuate exercise-induced improvements in cardiorespiratory fitness and insulin sensitivity in older adults (Konopka et al., 2019). While not a traditional "side effect," this interaction is relevant for longevity users who exercise regularly. The mechanism may involve metformin's suppression of mitochondrial reactive oxygen species (ROS) — the same ROS signals that trigger exercise-induced mitochondrial adaptations.

Contraindications

• Severe renal impairment (eGFR <30 mL/min/1.73m²) — contraindicated due to lactic acidosis risk
• Moderate renal impairment (eGFR 30–45) — use with caution, reduced dose, close monitoring
• Acute or chronic metabolic acidosis including diabetic ketoacidosis
• Hepatic impairment — reduces lactate clearance
• Hypersensitivity to metformin
• Acute conditions with risk of tissue hypoxia — heart failure, respiratory failure, sepsis, dehydration

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Off-Label Prescribing

Off-label prescribing — using an FDA-approved drug for an indication not specifically approved by the FDA — is legal and common in medical practice. Physicians may prescribe metformin for longevity based on their clinical judgment, the available evidence, and the patient's informed consent. Off-label prescribing accounts for an estimated 20% of all prescriptions in the United States.

For metformin specifically, off-label prescribing for longevity is facilitated by:

• Decades of safety data from diabetes use
• Very low cost as a generic medication
• Minimal abuse potential
• No DEA scheduling or controlled substance restrictions
• The existence of the TAME trial, which provides scientific legitimacy to the longevity hypothesis

The TAME Trial and Regulatory Precedent

The TAME trial is significant from a regulatory perspective because the FDA agreed to allow "aging" to serve as the basis for the trial's composite endpoint. This represented a paradigm shift: the FDA had not previously recognized aging itself as a condition amenable to pharmaceutical intervention. If TAME demonstrates benefit, it could establish precedent for:

• FDA approval of metformin for an aging-related indication
• A regulatory pathway for other aging interventions
• Insurance coverage of metformin for aging prevention (currently not covered for off-label longevity use)

WADA Status

Metformin is not prohibited by the World Anti-Doping Agency (WADA). It is not listed on the WADA Prohibited List and can be used by athletes without restriction. This contrasts with many other compounds studied for performance or health optimization.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

• With diabetes diagnosis: Fully covered by virtually all insurance plans, often with minimal copay ($0–$10/month). Metformin is on every major formulary.
• Off-label (longevity): Coverage varies. Some insurance plans will cover metformin regardless of diagnosis code if prescribed by a physician. Others require a qualifying diagnosis (diabetes, pre-diabetes, PCOS, metabolic syndrome). Many longevity patients pay out-of-pocket given the minimal cost.
• Discount programs: GoodRx, RxSaver, and pharmacy discount programs consistently list metformin at $4–$10/month without insurance.

Cost Comparison: Metformin vs. Other Longevity Interventions

Metformin's extremely low cost is one of the factors driving its adoption as a longevity intervention. Few other pharmaceutical candidates offer a comparable combination of mechanistic rationale, safety data, and affordability.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Does metformin extend lifespan in healthy (non-diabetic) humans?

Answer: This has not been established. The Bannister 2014 observational study found that metformin-treated diabetics had lower mortality than non-diabetic controls — but this does not demonstrate that metformin extends lifespan in already-healthy individuals. The population, confounders, and baseline risk profile differ substantially. The TAME trial is designed to address this question directly in non-diabetic older adults. Until results are available, no causal claim can be made (Bannister et al., 2014).

Question: Should I take metformin if I exercise regularly?

Answer: This is actively debated. Konopka et al. (2019) demonstrated that metformin (2,000 mg/day) blunted exercise-induced improvements in VO₂max and insulin sensitivity in older adults (Konopka et al., 2019). Exercise is itself one of the most robust longevity interventions. If metformin attenuates exercise benefits, the net healthspan effect in active individuals is uncertain. Some practitioners advise lower doses (500 mg/day), timing metformin away from exercise sessions, or skipping doses on training days — though none of these strategies have been tested in controlled trials. Others conclude that exercise benefits outweigh metformin's potential contribution and deprioritize metformin for physically active patients.

Question: How does metformin compare to rapamycin for longevity?

Answer: Both drugs target mTOR, but through different mechanisms and with different profiles:

• Rapamycin directly inhibits mTORC1 (and mTORC2 with chronic dosing); metformin inhibits mTOR indirectly through AMPK activation
• Rapamycin has more consistent lifespan extension data in mice across multiple strains (ITP studies)
• Metformin has far more human safety data (decades of use in millions of diabetic patients)
• Rapamycin has significant immunosuppressive effects; metformin does not
• Metformin is dramatically cheaper ($4–$15/month vs. $50–$200/month)
• Neither has prospective human longevity trial data; TAME is testing metformin specifically

These are different interventions with different risk-benefit profiles. Some longevity practitioners use both; the evidence does not currently support definitive preference for either in non-diabetic humans.

Question: Is metformin safe for people without diabetes?

Answer: Metformin's safety profile in diabetic populations is well-characterized over 60+ years of use. The Diabetes Prevention Program (DPP) trial demonstrated acceptable safety in a pre-diabetic (non-diabetic) population over several years. However, formal long-term safety data in metabolically healthy non-diabetic individuals taking metformin purely for longevity does not exist. The major known risks — GI side effects, B12 depletion, rare lactic acidosis with renal impairment — apply regardless of diabetes status. Hypoglycemia risk is low when metformin is used alone, as it does not stimulate insulin secretion.

Question: Does metformin cause weight loss?

Answer: Metformin is associated with modest weight loss or weight neutrality — typically 1–3 kg (2–7 lbs) over the first year, primarily through appetite reduction. It is not classified as a weight loss drug and is not FDA-approved for weight management. The weight effect is modest compared to GLP-1 receptor agonists (semaglutide, tirzepatide), which produce substantially greater weight loss.

Question: At what age should someone consider starting metformin for longevity?

Answer: There is no evidence-based answer. The TAME trial enrolls participants aged 65–79. Some longevity clinicians prescribe metformin to patients in their 40s–50s, particularly those with metabolic risk factors. The theoretical rationale for earlier use — intervening before age-related pathology becomes established — is not supported by human trial data. Starting age decisions are made on a case-by-case basis between patient and provider.

Question: Can I buy metformin without a prescription?

Answer: In the United States, Canada, EU, UK, and Australia, metformin requires a prescription. It is available over-the-counter in some other countries. Purchasing prescription medications without a prescription carries legal and health risks. A prescription ensures appropriate medical evaluation, contraindication screening, and monitoring.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Metformin is an inexpensive, widely available diabetes drug that has gained attention as a potential longevity intervention based on its effects on aging-associated pathways (AMPK activation, mTOR inhibition), observational mortality data, and animal lifespan studies.
• Observational data is suggestive but not conclusive. The Bannister 2014 study found metformin-treated diabetics had lower mortality than non-diabetic controls, but observational studies cannot establish causation and are subject to confounding.
• The TAME trial is the definitive test. Led by Nir Barzilai, it is the first FDA-approved clinical trial to test whether a drug can delay aging as a composite endpoint. Results are pending.
• Exercise interactions are a concern. Konopka 2019 demonstrated that metformin (2,000 mg/day) blunted exercise-induced fitness and metabolic improvements in older adults. This is relevant because exercise is itself a robust longevity intervention.
• Side effects are well-characterized: GI disturbance (common, usually manageable with ER formulation and gradual titration), vitamin B12 depletion (requires long-term monitoring), and rare lactic acidosis (primarily in renal impairment).
• Cost is minimal: $4–$15/month as a generic, making it one of the most accessible pharmaceutical interventions under consideration for longevity.
• Longevity use is off-label. Metformin is FDA-approved only for type 2 diabetes. Prescribing for longevity requires a physician's clinical judgment and patient's informed consent.
• The evidence base has significant gaps: No completed prospective longevity trial in humans; inconsistent animal data across strains; unresolved exercise interaction question; limited data in metabolically healthy non-diabetic populations.

Questions to Ask a Provider

• Given my metabolic profile and health status, does metformin make sense as a longevity intervention?
• How does metformin fit with my exercise program, given the Konopka 2019 data?
• What dose and formulation do you recommend, and what monitoring schedule is appropriate?
• Should I supplement B12 from the start, or monitor and supplement if levels decline?
• What are the realistic expectations for benefit, given that TAME trial results are not yet available?
• Are there other longevity interventions (lifestyle or pharmacological) I should prioritize over or alongside metformin?
• At what point should I reconsider metformin — what biomarkers or outcomes would warrant discontinuation?

Sources & Further Reading

Key Studies

• Bannister et al. (2014) — "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls" — Diabetes, Obesity and Metabolism
• Campbell et al. (2017) — "Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug" — Nature Medicine
• Konopka et al. (2019) — "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults" — Aging Cell
• Barzilai et al. (2016) — "Metformin as a tool to target aging" — Cell Metabolism

Animal Lifespan & Mechanistic Studies

• Martin-Montalvo et al. (2013) — "Metformin improves healthspan and lifespan in mice" — Nature Communications
• Onken & Driscoll (2010) — "Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1" — PLoS ONE
• Hardie (2013) — "AMPK: a target for drugs and natural products with effects on both diabetes and cancer" — Cell Metabolism

Clinical Trials & Diabetes Data

• UKPDS 34 (1998) — "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes" — Lancet
• Gandini et al. (2014) — "Metformin and cancer risk and mortality: a systematic review and meta-analysis" — Cancer Prevention Research

TAME Trial

• Barzilai et al. (2016) — "Metformin as a tool to target aging" — Cell Metabolism
• American Federation for Aging Research — TAME Trial Information

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.